Table 3

Multivariable linear regression for the association between MVPA and echocardiogram measures

OutcomeModel 1Model 2Model 3
LVMI, g/m20.04110.13180.1381
LVMI2.7/EDV−0.0014−0.0006−0.0006
RWT, ratio−0.0005−0.00010.0001
LAVI, mL/m20.1707*0.1808*0.1792*
EF, %0.05780.04480.0389
E/e′, ratio0.00370.02210.0259
GLS, %−0.069−0.0521−0.0539
GCS, %−0.2477*−0.2397*−0.2397*
SV, mL0.32770.31770.3174
RV peak S, cm/s0.05890.05900.0615
RV FAC, %0.00210.00190.0019
TRV Max, cm/s1.13671.13861.1597
TAPSE, cm0.00840.00820.0078
  • M1: demographics (age and sex).

  • M2: M1+systolic blood pressure, antihypertensive med use.

  • M3: M2+other cardiovascular disease modifiable factors (diabetes mellitus, current smoking and high-density lipoprotein).

  • Values are per 10 min/day light MVPA.

  • *P value <0.01.

  • E, peak early diastolic transmitral inflow velocities; EDV, end diastolic volume; e′, average of mitral early diastolic septal and lateral annular velocities; EF, ejection fraction; GCS, global circumferential strain; GLS, global longitudinal strain; LAVI, left atrial volume index; LVMI, left ventricular mass index; M, model; MVPA, moderate to vigorous PA; RV, right ventricular; RV FAC, RV fractional area change; RWT, relative valve thickness; SV, stroke volume; TAPSE, tricuspid annular plane systolic excursion; TRV, tricuspid regurgitation velocity.